Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study

The Lancet Haematology

Volumn 3, Issue 3, 2016, Pages e119-e127

  Green, Margaret L ^a,b   Leisenring, Wendy ^a,b   Xie, Hu ^a   Mast, T Christopher ^c   Cui, Yadong ^c   Sandmaier, Brenda M ^a,b   Sorror, Mohamed L ^a,b   Goyal, Sonia ^a   Özkök, Sezen ^a   Yi, Jessica ^a   Sahoo, Farah ^a   Kimball, Louise E ^a   Jerome, Keith R ^a,b   Marks, Morgan A ^c   Boeckh, Michael ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DEATH; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEWBORN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION; BLOOD DONOR; CYTOMEGALOVIRUS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; NEOPLASMS; PRESCHOOL CHILD; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD DONORS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEOPLASMS; RETROSPECTIVE STUDIES; VIRAL LOAD; YOUNG ADULT;

EID: 84958554767     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00289-6     Document Type: Article

References (29)

1. Marty, FM, Ljungman, P, Papanicolaou, GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 11 (2011), 284–292.
2. Marty, FM, Winston, DJ, Rowley, SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 369 (2013), 1227–1236.
3. Chemaly, RF, Ullmann, AJ, Stoelben, S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 370 (2014), 1781–1789.
4. Ljungman, P, Perez-Bercoff, L, Jonsson, J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 91 (2006), 78–83.
5. Gerna, G, Lilleri, D, Caldera, D, Furione, M, Zenone Bragotti, L, Alessandrino, EP, Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant 41 (2008), 873–879.
6. Green, ML, Leisenring, W, Stachel, D, et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant 18 (2012), 1687–1699.
7. Emery, VC, Sabin, CA, Cope, AV, Gor, D, Hassan-Walker, AF, Griffiths, PD, Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355 (2000), 2032–2036.
8. Gor, D, Sabin, C, Prentice, HG, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 21 (1998), 597–605.
9. Emery, VC, Cope, AV, Bowen, EF, Gor, D, Griffiths, PD, The dynamics of human cytomegalovirus replication in vivo. J Exp Med 190 (1999), 177–182.
10. Hayden, RT, Preiksaitis, J, Tong, Y, et al. Commutability of the 1st WHO international standard for human cytomegalovirus. J Clin Microbiol, 2015, 10.1128/JCM.01495-15 published online Aug 12.
11. Nichols, WG, Corey, L, Gooley, T, Davis, C, Boeckh, M, High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 185 (2002), 273–282.
12. Green, ML, Leisenring, WM, Xie, H, et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122 (2013), 1316–1324.
13. Boeckh, M, Huang, M, Ferrenberg, J, et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 42 (2004), 1142–1148.
14. Ljungman, P, Griffiths, P, Paya, C, Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 (2002), 1094–1097.
15. Rizzo, JD, Causes of Death. http://www.cibmtr.org/meetings/materials/crpdmc/pages/Feb12Cause.aspx, Feb 1, 2012 (accessed March 21, 2015).
16. Sorror, ML, Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005), 2912–2919.
17. Deayton, JR, Sabin, CA, Johnson, MA, Emery, VC, Wilson, P, Griffiths, PD, Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet 363 (2004), 2116–2121.
18. Hiwarkar, P, Gaspar, HB, Gilmour, K, et al. Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. Bone Marrow Transplant 48 (2013), 803–888.
19. Kojima, E, Shirasaka, T, Anderson, B, et al. Monitoring the activity of antiviral therapy for HIV infection using a polymerase chain reaction method coupled with reverse transcription. AIDS 7:suppl 2 (1993), S101–S105.
20. Mellors, JW, Rinaldo, CR, Gupta, P, White, RM, Todd, JA, Kingsley, LA, Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272 (1996), 1167–1170.
21. Mellors, JW, Munoz, A, Giorgi, JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126 (1997), 946–954.
22. Holland, CA, Ellenberg, JH, Wilson, CM, et al. Relationship of CD4+ T cell counts and HIV type 1 viral loads in untreated, infected adolescents. Adolescent medicine HIV/AIDS research network. AIDS Res Hum Retroviruses 16 (2000), 959–963.
23. Cantoni, N, Hirsch, HH, Khanna, N, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant 16 (2010), 1309–1314.
24. Elmaagacli, AH, Steckel, NK, Koldehoff, M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 118 (2011), 1402–1412.
25. Takenaka, K, Nishida, T, Asano-Mori, Y, et al. Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Biol Blood Marrow Transplant, 2015, 10.1016/j.bbmt.2015.07.019 published online July 23.
26. Ramanathan, M, Teira, P, Battiwalla, M, et al. Early CMV reactivation still remains a cause of increased transplant related mortality in the current era: a CIBMTR analysis. Blood, 124(suppl), 2014 abstr 47.
27. Boeckh, M, Nichols, WG, Chemaly, RF, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation. Annal Intern Med 162 (2015), 1–10.
28. Ito, S, Pophali, P, CO, W, et al. CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplant 48 (2013), 1313–1316.
29. Sorror, M, Storer, B, Sandmaier, BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112 (2008), 1992–2001.